Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 3

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × saponin QA-21V1 × Genitourinary × Clear all
NCT00036933 2013-03-25

Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
9 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003819 2013-03-19

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
21 enrolled
Genitourinary

Prostatic Neoplasms

NCT00004929 2013-01-31

Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
15 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡